Abilita Bio, Inc. logo

Abilita Bio, Inc.

Abilita Bio is focused on developing technologies to enable discovery and development of drugs targeting MembraneProteins, including GPCRs and ionchannels. Abilita Bio focuses on enabling discovery and development of drugs targeting membrane proteins, including G Protein Coupled Receptors (GPCRs) and ion channels and is currently incubating in JLabs San Diego.

20
Management
23
Technology
0
Deals/Partnering
14
Research Pipeline
14
Funding
BioStartup's Score 14 / 50

KEY DETAILS

Websitehttp://www.abilitabio.com
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
3210 Merryfield Row, 92121
San Diego
United States
Email
Contact Number

Abilita Bio focuses on enabling discovery and development of drugs targeting membrane proteins, including G Protein Coupled Receptors (GPCRs) and ion channels and is currently incubating in JLabs San Diego.

No review box found! Insert a valid box ID.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/abilita-bio-inc-” connections=”true” suffix=””]

Abilitas proprietary Enabled Membrane Proteins (EMPsé) technology platform uses a cell-based directed evolution system to optimize key membrane protein properties, while preserving native structure and pharmacology.

No review box found! Insert a valid box ID.

 

Abilita Bio has established several global collaborations around the Enabled Membrane Proteins (EMPé) platform, including proof of concept agreements with three undisclosed top-15 pharmaceutical companies.

In Sep 2016, Abilita Bio was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to develop therapeutic antibodies targeting G Protein-Coupled Receptors (GPCRs) involved in the metastasis of breast cancer, including prostaglandin E2 receptor 2 (EP2), prostaglandin E2 receptor 4 (EP4), and C-C chemokine receptor 7 (CCR7).